A biotechnology company using placental mesenchymal stem cells to develop cell therapies for medical conditions such as inflammation, ischemia, hematological disorders, and radiation.
On June 17, 2015 Pluritstem Therapeutics received a grant worth $2.9 million from an undisclosed source.